Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 12/20 | 0.65 |
| ▸ | PLK3 | Q9H4B4 | 5/20 | 0.65 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.51 |
| ▸ | LTC4S | Q16873 | 1/20 | 0.51 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.50 |
| ▸ | BCL2A1 | Q16548 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2275929 | 0.91 | KMT2A (0.62) | PLK1PLK3MEN1MAPTKMT2A | |
| SCHEMBL2274146 | 0.90 | PLK1 (0.56) | PLK1PLK3MEN1MAPTKMT2A | |
| SCHEMBL2271421 | 0.88 | DHODH (0.63) | PLK1PLK3MEN1MAPTKMT2A | |
| SCHEMBL2270925 | 0.88 | PLK1 (0.57) | PLK1PLK3MEN1MAPTKMT2A | |
| SCHEMBL2270906 | 0.88 | MEN1 (0.56) | PLK1PLK3MEN1MAPTKMT2A | |
| SCHEMBL2273979 | 0.88 | ALDH1A1 (0.58) | PLK1PLK3MEN1MAPTKMT2A | |
| SCHEMBL2274700 | 0.87 | MEN1 (0.55) | PLK1PLK3MEN1MAPTKMT2A | |
| SCHEMBL2271182 | 0.87 | PLK1 (0.53) | PLK1PLK3MEN1MAPTKMT2A | |
| SCHEMBL2271933 | 0.87 | MEN1 (0.54) | PLK1PLK3MEN1MAPTKMT2A | |
| SCHEMBL2273122 | 0.86 | PLK1 (0.57) | PLK1PLK3SLC16A3MEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7999132-B2 | Anthranilic acid derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2011-08-16 | — | — | US | disclosed |
| US-20090240052-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-09-24 | — | — | US | disclosed |
| EP-1820795-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2007-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090240052-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | MMP13, MMP26, MMP11 | PLK1 4227/4885PLK3 3893/4885SLC16A3 380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.